Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Phase one

<< Previous

Bullboard Posts

Next >>

Comment by PTBaileyon Feb 24, 2022 8:39am

70 Views

Post# 34457167

RE:Phase one

I think you need to read there again, there was no arguement.

Unless Highskies took it that way but I don't think so.

And the thing about patience is the more its tested the more you get. So be patient. Salzman has to be highly motivated to get the info they are looking for, which is minor compared to everything they have prestented to this point.

If we don't finish Phase 1 by end of April but now maybe its May will it matter a year from now.

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale